Advanced search    

Search: authors:"Ruth Roberts"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Living with conduct problem youth: family functioning and parental perceptions of their child

, Cardiff University , Tower Building, 70 Park Place, Cardiff CF10 3AT , UK 1 Ruth Roberts Parenting children with conduct problems (CP) is challenging, yet very little is known about the impact of the

Drug-Induced Oxidative Stress and Toxicity

. Deavall, Elizabeth A. Martin, Judith M. Horner, and Ruth Roberts Safety Assessment, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK Received 1 March 2012; Revised 26 April 2012; Accepted 29 April

Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease

Eric Boitier 0 Jean-Charles Gautier 0 Ruth Roberts 0 0 Address: Aventis Pharma Drug Safety Evaluation, Centre de Recherche de Paris , 13 Quai Jules Guesde 94403, Vitry sur Seine, Paris , France

Culture environment modulates maturation and metabolism of human oocytes

Ruth Roberts 0 Stephen Franks 0 Kate Hardy 0 0 Department of Reproductive Science and Medicine, Institute of Reproductive and Developmental Biology, The Wolfson and Weston

Downregulation of Lactoferrin by PPARα Ligands: Role in Perturbation of Hepatocyte Proliferation and Apoptosis

PPARα (peroxisome proliferator activated receptor α) is a transcription factor that mediates the rodent liver tumorigenic responses to peroxisome proliferators via regulation of genes that remain to be identified. Using microarray gene expression profiling of mRNA from wild type versus PPARα null mice, we detected a 3- to 7-fold downregulation of hepatic lactoferrin (LF) in...

Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats

The development of the dual peroxisome proliferator–activated receptor (PPAR) α/γ agonist tesaglitazar as an oral antidiabetic was recently discontinued. Here we present tumor data from a 2-year carcinogenicity study in rats given 0.3, 1, 3, and 10 μmol/kg tesaglitazar is presented with focus on the findings of subcutaneous fibrosarcomas. To investigate the mechanism for...